Diabetes, Vol 46, Issue 1 125-132, Copyright © 1997 by American Diabetes Association

ARTICLES

Macrovascular disease is associated with increased plasma apolipoprotein A-IV levels in NIDDM

BL Verges, L Lagrost, G Vaillant, JM Petit, M Cohen, P Gambert and JM Brun
Department of Endocrinology and Diabetology, University of Dijon, France.

Apolipoprotein A-IV (apoA-IV) might play an important role in lipoprotein metabolism, including modulation of triglyceride-rich lipoprotein catabolism, reverse cholesterol transport and cholesteryl ester transfer protein (CETP) activity. Increased apoA-IV levels have been reported in plasma from NIDDM patients. The aim of the present study was to look for a possible association between plasma apoA-IV level and prevalence of macrovascular disease in NIDDM. One hundred and thirty-six NIDDM patients were studied (71 men, 65 women). Macrovascular disease was assessed in each patient by a standardized questionnaire, physical examination, resting electrocardiogram (ECG), and laboratory evaluation (ankle/arm blood pressure ratio, continuous wave Doppler velocimetry). Moreover, patients without any history of coronary heart disease and showing a normal resting ECG underwent a bicycle exercise test or a dipyridamole thallium scintigraphy to detect possible silent myocardial ischemia. Among the 136 NIDDM patients, 56 had macrovascular disease. ApoA-IV levels were significantly higher in NIDDM patients with macrovascular disease than in NIDDM patients without macrovascular disease (20.9 +/- 8.6 vs. 13.3 +/- 5.3 mg/dl; P < 0.001). The influence of different factors, such as age, BMI, cigarette smoking, hypertension, total cholesterol, triglycerides, HDL cholesterol, apoA-IV level, apoA-IV phenotype, fasting glycemia, fasting C-peptide, and microalbuminuria, on the prevalence of macrovascular disease was analyzed using a logistic regression model. In the univariate analysis, apoA-IV level (P < 0.00001), age (P = 0.0087), hypertension (P = 0.012), microalbuminuria (P = 0.018), triglycerides (P = 0.02), and fasting C-peptide (P = 0.03) were positively associated with macrovascular disease. In the multivariate analysis, macrovascular disease was positively associated only with apoA-IV (P < 0.0001) and age (P = 0.003) and negatively associated with HDL cholesterol (P = 0.013). These results indicate that increased plasma apoA-IV level is associated with an increased prevalence of macrovascular disease in NIDDM. Moreover, apoA-IV, in NIDDM patients, appears to be a better marker for macrovascular disease than triglycerides.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				G. C. Shearer, J. W. Newman, B. D. Hammock, and G. A. Kaysen Graded Effects of Proteinuria on HDL Structure in Nephrotic Rats J. Am. Soc. Nephrol., May 1, 2005; 16(5): 1309 - 1319. [Abstract] [Full Text] [PDF]

				M. Liu, T. Doi, and P. Tso Regulation of Intestinal and Hypothalamic Apolipoprotein A-IV Experimental Biology and Medicine, November 1, 2003; 228(10): 1181 - 1189. [Abstract] [Full Text] [PDF]

				F. Kronenberg, E. Kuen, E. Ritz, P. Konig, G. Kraatz, K. Lhotta, J. F. E. Mann, G. A. Muller, U. Neyer, W. Riegel, et al. Apolipoprotein A-IV Serum Concentrations Are Elevated in Patients with Mild and Moderate Renal Failure J. Am. Soc. Nephrol., February 1, 2002; 13(2): 461 - 469. [Abstract] [Full Text] [PDF]

				B. Verges, B. Guerci, V. Durlach, C. Galland-Jos, J. L. Paul, L. Lagrost, and P. Gambert Increased plasma apoA-IV level is a marker of abnormal postprandial lipemia: a study in normoponderal and obese subjects J. Lipid Res., December 1, 2001; 42(12): 2021 - 2029. [Abstract] [Full Text] [PDF]

				T. Doi, M. Liu, R. J. Seeley, S. C. Woods, and P. Tso Effect of leptin on intestinal apolipoprotein AIV in response to lipid feeding Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2001; 281(3): R753 - R759. [Abstract] [Full Text] [PDF]

				G. CANDIANO, L. MUSANTE, M. CARRARO, L. FACCINI, L. CAMPANACCI, C. ZENNARO, M. ARTERO, F. GINEVRI, F. PERFUMO, R. GUSMANO, et al. Apolipoproteins Prevent Glomerular Albumin Permeability Induced In Vitro by Serum from Patients with Focal Segmental Glomerulosclerosis J. Am. Soc. Nephrol., January 1, 2001; 12(1): 143 - 150. [Abstract] [Full Text]

				F. Kronenberg, M. Stuhlinger, E. Trenkwalder, F. S. Geethanjali, O. Pachinger, A. von Eckardstein, and H. Dieplinger Low apolipoprotein A-IV plasma concentrations in men with coronary artery disease J. Am. Coll. Cardiol., September 1, 2000; 36(3): 751 - 757. [Abstract] [Full Text] [PDF]

				S. X. Cao, J. M. Dhahbi, P. L. Mote, and S. R. Spindler Genomic profiling of short- and long-term caloric restriction effects in the liver of aging mice PNAS, September 11, 2001; 98(19): 10630 - 10635. [Abstract] [Full Text] [PDF]